Several practice guidelines have pointed out that perineural invasion, lymphovascular invasion, perforation, obstruction, poor differentiation, T4 lesion, harvesting less than 12 lymph nodes, positive margins, mucinous type, and high pre-operative carcinoembryonic antigen (CEA) levels are high-risk factors in stage II CRC and only suggested postoperative adjuvant chemotherapy in these high-risk patients with stage II CRC [9, 11, 12]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.